At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 4, 2026 at 16:10 ET
Vir Biotechnology reported Q3 2026 net loss of $96.3M ($0.57 per share), narrower than the $163.1M loss in Q3 2025, driven by a $75M non-recurring milestone expense in the prior year. The company ended the quarter with $901.3M in cash and investments, entered a Gilead collaboration for up to $1.74B in milestones, and expects topline Phase 3 ECLIPSE 1 data in Q4 2026.
- Q3 2026 net loss of $96.3M ($0.57 per share) vs $163.1M ($1.17 per share) in Q3 2025
- Cash, cash equivalents and investments of $901.3M as of September 30, 2026, a decrease of $106.5M during Q3
- Entered collaboration with Gilead for three PRO-XTEN dual-masked TCE candidates; received $90M upfront including $25M equity investment at 30% premium
- VIR-5500 received FDA Fast Track designation and achieved proof of concept; pivotal trials expected to begin in 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access